

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells


Daniele Cretella⁺, Claudia Fumarola⁺, Mara Bonelli^{*}, Roberta Alfieri, Silvia La Monica, Graziana Digiaco, Andrea Cavazzoni, Maricla Galetti, Daniele Generali, Pier Giorgio Petronini.

*Correspondence to:

Mara Bonelli - Department of Medicine and Surgery, University of Parma, Italy

Tel +39 0521 903766

E mail mara.bonelli@unipr.it



Supplementary Fig.1 Palbociclib combined with 5-FU induces different effects on cell proliferation depending on the treatment schedule

a MDA-MB-231 and HCC38 cells were treated with increasing concentrations of 5-FU. After 72h cell proliferation was evaluated by CV staining. Data are expressed as EC₅₀ values and are means \pm SD of three independent experiments. MDA-MB-231 and HCC38 cells were treated with 0.5 μM palbociclib alone or in combination with increasing concentrations of 5-FU (**b**, **c**) or with 0.5 μM palbociclib for 24h followed by exposure to increasing concentrations of 5-FU alone for 48h (**d**, **e**). After 72h cell proliferation was assessed by CV assay. The effect of the drug combinations was evaluated using the Bliss interaction model. Data are mean values \pm SD of three independent experiments.